POLD1 and melanoma: Given the variety of immuno-oncology treatments currently in use for therapies in patients with different cancer types, including melanoma, NSCLC, CRC, and HCC [97,108], novel research examining the relationship between the expression of the POLD1 protein and the clinical outcomes in patients receiving immunotherapy would be of great importance.